FBXW7 Loss-of-function

CI-VAR-00002528Explore in graph →CIViC 637

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
FBXW7 Loss-of-function	Sirolimus	Predictive	D	Supports Sensitivity Response	4	accepted	EID1632 FBXW7 was shown to target mTOR for ubiquitination and degradation. A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of th… (full text at CIViC) PMID 18787170 · Mao et al., 2008 · Open in CIViC	civic
Renal Cell Carcinoma1
FBXW7 Loss-of-function	Everolimus	Predictive	E	Supports Sensitivity Response	2	accepted	EID1628 mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-depende… (full text at CIViC) PMID 24253377 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.